Strong R&D infrastructure but slow to market - Recensione dipendente - Senior Scientist presso Lupin

2,0
19 mag 2026
Consiglia
Gradimento del CEO
Pronostico commerciale

Vantaggi

Good infrastructure in R&D, manufacturing, robust compliance set up.

Svantaggi

Compared to Pharma biologics seems weak. Long timelines from inception to market delivery. In comparison, other Indian biosimilar sponsors have gone far ahead.

Esplora altre recensioni su Lupin

5,0
21 nov 2025
Consiglia
Gradimento del CEO
Pronostico commerciale

Vantaggi

- good team - collaborative - amazing mentors

Svantaggi

- office location, no public transport

3,0
3 mag 2026
Consiglia
Gradimento del CEO
Pronostico commerciale

Vantaggi

Broad career exposure that you otherwise won't get in large companies.

Svantaggi

Management directionless, indecisive, everyone just blaming everyone else,

Vedi recensioni per: Utile|Valutazione|Data|Tutto